Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Sei Investments Co.

Sei Investments Co. lessened its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 38.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,164 shares of the company's stock after selling 13,085 shares during the quarter. Sei Investments Co. owned approximately 0.07% of Krystal Biotech worth $3,316,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. BNP Paribas Financial Markets boosted its position in Krystal Biotech by 346.8% during the third quarter. BNP Paribas Financial Markets now owns 10,433 shares of the company's stock worth $1,899,000 after acquiring an additional 8,098 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Krystal Biotech by 3.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company's stock worth $840,000 after purchasing an additional 153 shares during the last quarter. Hilltop Holdings Inc. purchased a new stake in shares of Krystal Biotech in the third quarter valued at approximately $209,000. State Street Corp increased its holdings in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in Krystal Biotech by 15.1% during the third quarter. Wellington Management Group LLP now owns 12,680 shares of the company's stock worth $2,308,000 after buying an additional 1,660 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

KRYS has been the subject of several analyst reports. Chardan Capital upped their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group started coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and an average target price of $220.00.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company's stock.

Krystal Biotech Stock Down 4.4 %

Shares of KRYS traded down $7.32 during trading on Tuesday, reaching $158.69. 394,639 shares of the company traded hands, compared to its average volume of 293,205. The stock has a 50-day simple moving average of $173.44 and a 200-day simple moving average of $172.60. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The stock has a market cap of $4.57 billion, a PE ratio of 53.07 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the previous year, the company earned $0.30 earnings per share. The firm's quarterly revenue was up 116.4% compared to the same quarter last year. On average, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).